Beyond Air ( (XAIR) ) has released its Q1 earnings. Here is a breakdown of the information Beyond Air presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company that focuses on utilizing nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors. The company has developed the LungFit system, which is approved for use in the treatment of hypoxic respiratory failure in neonates.
In its fiscal first quarter of 2026, Beyond Air reported a significant increase in revenues, reaching $1.8 million, a 157% rise compared to the same period last year. The company attributes this growth to the increased demand for its LungFit PH system, particularly in the U.S., and the expansion of its distribution network internationally.
Key financial highlights include a gross profit of $0.2 million for the quarter, a notable improvement from the previous year’s gross loss. Additionally, research and development expenses decreased significantly, contributing to a reduced net loss of $7.7 million compared to $12.2 million in the previous year. The company also secured a national group purchasing agreement with Premier, Inc., enhancing its market reach.
Beyond Air continues to advance its clinical programs, including the development of ultra-high concentration nitric oxide technology for solid tumors and a preclinical program for autism spectrum disorder. The company remains optimistic about its future revenue growth, reaffirming its guidance of $12 to $16 million for the fiscal year 2026.
Looking ahead, Beyond Air aims to sustain its revenue growth trajectory by expanding its market presence and advancing its clinical pipeline. The company’s management remains committed to leveraging its innovative technologies to improve patient outcomes across various therapeutic areas.